Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1155/2015/343828 http://scihub22266oqcxt.onion/10.1155/2015/343828 C4430647!4430647!26064107     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Int+J+Endocrinol 2015 ; 2015 (ä): ä Nephropedia Template TP {{tp|p=26064107|t=2015. Noninvasive Assessment of Fibrosis in Patients with Nonalcoholic Fatty Liver Disease |pdf=|usr=}}{{26064107}} gab.com Text Noninvasive Assessment of Fibrosis in Patients with Nonalcoholic Fatty Liver Disease JO: Int J Endocrinol http://www.kidney.de/pget.php?&tw=1&pmid=26064107 #FOAvip Nonalcoholic fatty liver disease (NAFLD) is prevalent in 20?25% of the general population and is associated with metabolic risk factors such as obesity, diabetes mellitus, and dyslipidemia. Histologically, NAFLD ranges from simple steatosis to nonalcoholic steatohepatitis (NASH), fibrosis, and cirrhosis. As NASH develops in only 10?15% of patients with NAFLD, it is not practical to biopsy all patients who present with NAFLD. Noninvasive fibrosis tests have been extensively developed recently and offer alternatives for staging fibrosis. Despite their increasing use, such tests cannot adequately differentiate simple steatosis from NASH. At present, such tests can be used as first line tests to rule out patients without advanced fibrosis and thus prevent unnecessary secondary care referrals in a significant number of patients. In this review we present the evidence for the use of noninvasive fibrosis tests in patients with NAFLD. Twit Text FOAVip Noninvasive Assessment of Fibrosis in Patients with Nonalcoholic Fatty Liver Disease ????Int J Endocrinol http://www.kidney.de/pget.php?&tw=1&pmid=26064107 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=26064107 #FOAvip English Wikipedia <ref>{{Cite pmid|26064107}}</ref> Noninvasive Assessment of Fibrosis in Patients with Nonalcoholic Fatty Liver Disease #MMPMID26064107 Buzzetti E; Lombardi R; De Luca L; Tsochatzis EA Int J Endocrinol 2015[]; 2015 (ä): ä PMID26064107show ga Nonalcoholic fatty liver disease (NAFLD) is prevalent in 20?25% of the general population and is associated with metabolic risk factors such as obesity, diabetes mellitus, and dyslipidemia. Histologically, NAFLD ranges from simple steatosis to nonalcoholic steatohepatitis (NASH), fibrosis, and cirrhosis. As NASH develops in only 10?15% of patients with NAFLD, it is not practical to biopsy all patients who present with NAFLD. Noninvasive fibrosis tests have been extensively developed recently and offer alternatives for staging fibrosis. Despite their increasing use, such tests cannot adequately differentiate simple steatosis from NASH. At present, such tests can be used as first line tests to rule out patients without advanced fibrosis and thus prevent unnecessary secondary care referrals in a significant number of patients. In this review we present the evidence for the use of noninvasive fibrosis tests in patients with NAFLD. äNoninvasive Assessment of Fibrosis in Patients with Nonalcoholic Fatty(epmc).pdf DeepDyve Pubget Overpricing